MYBPC3 and cardiomyopathy: Finally, several initiatives are currently targeting gene therapy for cardiomyopathies caused by mutations in MYBPC3 and LAMP2 (by gene replacement), while others for TNNI3, PRKAG2 and DSP‐associated disease are being developed (Argirò et al. 2024; Lairez et al. 2024).